德谷门冬双胰岛素联合米格列醇治疗2型糖尿病的临床疗效及安全性研究

Study on Clinical Efficacy and Safety of Insulin Degludec and Insulin Aspart Combined with Miglitol in Treating Type 2 Diabetes Mellitus

目的:研究德谷门冬双胰岛素联合米格列醇治疗2型糖尿病的临床疗效及安全性。方法:选取2022年8月—2023年8月湛江中心人民医院收治的198例2型糖尿病患者作为研究对象,采用随机信封法分为对照组和观察组,每组各99例。对照组采用德谷门冬双胰岛素治疗,观察组采用德谷门冬双胰岛素联合米格列醇治疗。比较两组体质指数(BMI)、血糖指标[空腹血糖(FPG)、餐后2 h血糖(2 hPG)和糖化血红蛋白(HbA1c)]、血脂指标[甘油三脂(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)]、肝功能指标[天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)]、胰岛素总使用剂量和不良反应发生情况。结果:治疗后2、4、8、12周,观察组BIM、FPG、2 hPG、HbA1c水平均低于对照组,差异有统计学意义(P<0.05);治疗后2、4、8、12周,观察组TG、TC、LDL均低于对照组,HDL高于对照组,差异有统计学意义(P<0.05);治疗后2、4、8、12周,两组AST、ALT比较,差异无统计学意义(P>0.05);治疗12周后,观察组胰岛素总使用量低于对照组,差异有统计学意义(P<0.05);两组低血糖发生率以及不良事件总发生率比较,差异无统计学意义(P>0.05)。结论:德谷门冬双胰岛素联合米格列醇在治疗2型糖尿病中具有较好的临床疗效和安全性,其能有效改善患者糖脂代谢,降低胰岛素总使用量,且低血糖发生率较低,不会加重肝脏负担。

Objective:To study the clinical efficacy and safety of insulin degludec/insulin aspart combined with miglitol in the treatment of type 2 diabetes mellitus(T2DM).Method:A total of 198 patients with type 2 diabetes admitted to Central People's Hospital of Zhanjiang from August 2022 to August 2023 were selected as the study objects and divided into control group and observation group by random envelope method,with 99 cases in each group.The control group was treated with Insulin Degludec and Insulin Aspart,and the observation group was treated with Degludec and Insulin Aspart combined with miglitol.Body mass index(BMI),blood glucose index[fasting plasma glucose(FPG),2 h postprandial plasma glucose(2hPG)and glycosylated hemoglobin(HbA1c)],lipid indexes[triglycerides(TG),total cholesterol(TC),low density lipoprotein(LDL)and high density lipoprotein(HDL)],liver function indexes[aspartate aminotransferase(AST),alanine aminotransferase(ALT)],total insulin dose and occurrence of adverse reactions condition were compared between the two groups.Result:The BMI,FPG,2 h PG and HbA1c in observation group were lower than those in control group 2,4,8 and 12 weeks after treatment(P<0.05).The levels of TG,TC and LDL in observation group 2,4,8 and 12 weeks after treatment were lower than those in control group,while the level of HDL was higher than that in control group(P<0.05).There were no statistical differences in AST and ALT between the two groups 2,4,8 and 12 weeks after treatment(P>0.05).The total dosage of insulin after 12 weeks of treatment was less in observation group than that in control group(P<0.05).The incidence rate of hypoglycemia and total incidence rate of adverse events revealed no statistical differences between groups(P>0.05).Conclusion:Degludec and Insulin Aspartcombined with miglitol has good clinical efficacy and safety in the treatment of type 2 diabetes mellitus.It can effectively improve the glucolipid metabolism and reduce the total dosage of insulin,and it has low incidence rate of hypoglycemia and will not increase the burden on the liver.